title: Substantial variation in post-engraftment infection prophylaxis and revaccination practice in autologous stem cell transplant patients.
abstract: There is a paucity of evidence supporting the necessity or duration of Pneumocystis jirovecii and antiviral prophylaxis as well as revaccination following autologous stem cell transplant (ASCT). A survey aimed at evaluating these policies was distributed to 34 ASCT centres across Australasia. The 26 survey respondents demonstrated significant heterogeneity in their infection prophylaxis and revaccination strategy post-transplant despite the availability of consensual guidelines.
authors.affiliation: Department of Clinical Haematology, Austin Health, Melbourne, Victoria, Australia.
authors.forename: H Y
authors.initials: HY
authors.lastname: Lim
authors.affiliation: Department of Clinical Haematology, Austin Health, Melbourne, Victoria, Australia.
authors.forename: A
authors.initials: A
authors.lastname: Grigg
mesh_terms: D001315:Australia / Q000453:epidemiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods / Q000592:standards*; D009181:Mycoses / Q000209:etiology / Q000517:prevention & control*; D009520:New Zealand / Q000453:epidemiology; D056990:Post-Exposure Prophylaxis / Q000379:methods / Q000592:standards*; D011795:Surveys and Questionnaires; D014182:Transplantation, Autologous / Q000009:adverse effects; D014777:Virus Diseases / Q000209:etiology / Q000517:prevention & control*
keywords: Pneumocystis jirovecii; antiviral; autologous stem cell transplant; prophylaxis; revaccination